Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

/in

First patient dosed in France, expanding the DOMISOL study beyond Australia DT‑7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program Montreal, Canada – Strasbourg, France – Boston, United States, April 9, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today […]

Read more

Hansa Biopharma to host Q1 2026 interim results conference call

/in

Lund, Sweden, 8 April, 2026. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), will publish its interim report for January – March 2026 on 23 April, 2026. Interested parties may join the Company’s quarterly conference call on the same date at 14:00 CEST / 8:00 AM EDT. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan […]

Read more

SonoNeu exits stealth as key part of US Government-funded research program worth up to $41.3m to advance sonogenetics into clinic

/in

Sonogenetics, discovered by SonoNeu founder Sreekanth Chalasani, is a new modality using ultrasound to precisely control specific cells ‘tagged’ with special proteins SonoNeu is part of a collaborative project, also comprising six leading US institutions, to advance sonogenetics research Project awarded up to $41.3m by Advanced Research Projects Agency for Health (ARPA-H), an agency within […]

Read more

Grant of first POLB 001 cancer immunotherapy-induced CRS patent

/in

Significant milestone for Poolbeg’s global intellectual property portfolio 31 March 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from IP Australia, […]

Read more

Hansa Biopharma publishes 2025 Annual and Sustainability Reports

/in

Lund, Sweden, 26 March 2026. Hansa Biopharma AB, “Hansa” or the “Company” (Nasdaq Stockholm: HNSA), today published its Annual and Sustainability Reports for 2025. Peter Nicklin, Chair of the Board, Hansa Biopharma, said: “2025 was a year of transformation for Hansa Biopharma, marked by the appointment of Renée Aguiar‑Lucander as our new CEO with a clear […]

Read more